Characterization of hepatitis C RNA-containing particles from human liver by density and size by Nielsen, Søren U. et al.
Characterization of hepatitis C RNA-containing
particles from human liver by density and size
Søren U. Nielsen,
1 Margaret F. Bassendine,
1 Caroline Martin,
13
Daniel Lowther,
14 Paul J. Purcell,
1 Barnabas J. King,
11 Dermot Neely
2
and Geoffrey L. Toms
1
Correspondence
Søren U. Nielsen
s.u.nielsen@ncl.ac.uk
1Liver Research Group, Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne NE2
4HH, UK
2Department of Clinical Biochemistry, Royal Victoria Infirmary, Newcastle upon Tyne, UK
Received 3 January 2008
Accepted 20 June 2008
Hepatitis C virus (HCV) particles found in vivo are heterogeneous in density and size, but their
detailed characterization has been restricted by the low titre of HCV in human serum. Previously,
our group has found that HCV circulates in blood in association with very-low-density lipoprotein
(VLDL). Our aim in this study was to characterize HCV RNA-containing membranes and
particles in human liver by both density and size and to identify the subcellular compartment(s)
where the association with VLDL occurs. HCV was purified by density using iodixanol gradients
and by size using gel filtration. Both positive-strand HCV RNA (present in virus particles) and
negative-strand HCV RNA (an intermediate in virus replication) were found with densities below
1.08 g ml
”1. Viral structural and non-structural proteins, host proteins ApoB, ApoE and
caveolin-2, as well as cholesterol, triglyceride and phospholipids were also detected in these low
density fractions. After fractionation by size with Superose gel filtration, HCV RNA and viral
proteins co-fractionated with endoplasmic reticulum proteins and VLDL. Fractionation on
Toyopearl, which separates particles with diameters up to 200 nm, showed that 78% of HCV
RNA from liver was .100 nm in size, with a positive-/negative-strand ratio of 6:1. Also, 8% of
HCV RNA was found in particles with diameters between 40 nm and 70 nm and a positive-/
negative-strand ratio of 45:1. This HCV was associated with ApoB, ApoE and viral glycoprotein
E2, similar to viral particles circulating in serum. Our results indicate that the association between
HCV and VLDL occurs in the liver.
INTRODUCTION
Hepatitis C virus (HCV) belongs to the family Flaviviridae
and is infectious in humans and chimpanzees (Lindenbach
& Rice, 2001). There are some biochemical and biophysical
data for HCV virus particles from infected hosts (Andre ´
et al., 2002; Petit et al., 2005; Roingeard et al., 2004) but the
characterization of native virus particles has been difficult
due to the low titre of HCV in serum. Analysis of HCV
from human serum by immunoprecipitation and Western
blotting shows that the virus particle contains glycopro-
teins E1 and E2 (Petit et al., 2005), and that virus particles
are associated with apolipoprotein B and E (ApoB and
ApoE) (Andre ´ et al., 2002; Nielsen et al., 2006). A more
detailed structural analysis of native HCV particles from
infected hosts requires higher titres of virus. However, the
characterization of HCV produced in vitro has been
facilitated by two scientific breakthroughs.
The first breakthrough in the characterization of HCV
produced in vitro was the development of the replicon
system (Lohmann et al., 1999). In this system, HCV
(genotypes 1b and 2a) replicates in Huh-7 human
hepatoma cells and produces all HCV structural and
non-structural (NS) proteins, as well as positive- and
negative-strand HCV RNA (Lohmann et al., 1999;
Pietschmann et al., 2002; Quinkert et al., 2005). Although
virus particles are not secreted from Huh-7 cells transfected
with the replicon, the system has enabled detailed studies
of subcellular structures involved in HCV replication and
characterization of the HCV replication complex. The
replication complex is found inside a membranous web
which also contains lipid rafts (Gosert et al., 2003; Shi et al.,
2003) and has a low density (¡1.10 g ml
21) (El-Hage &
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partially purified replication complexes are involved in
lipid metabolism (Huang et al., 2007). Further evidence for
the role of host lipid metabolism in HCV replication comes
from Kapadia & Chisari (2005). This study demonstrated
that HCV RNA replication is increased in Huh-7 cells
when the growth medium is supplemented with mono-
unsaturated fatty acids, but reduced when cells are grown
in the presence of polyunsaturated fatty acids.
The second breakthrough in the characterization of HCV
produced in vitro was the identification of the JFH-1 strain
(Kato et al., 2001). This genotype 2a virus replicates in cell
culture in Huh-7 and Huh-7.5 cells to produce infectious
virus (Lindenbach et al., 2005; Wakita et al., 2005). The
buoyant densities of virus produced from the JFH-1 strain
cover a wide range between 1.03 g ml
21 and 1.16 g ml
21.
The peak of HCV RNA coincides with fractions of lowest
infectivity that have a density around 1.14 g ml
21,a
sedimentation coefficient of 200 S and a diameter of
approximately 55–70 nm (Gastaminza et al., 2006; Wakita
et al., 2005). The buoyant density of infectious virus
produced in vitro by the JFH-1 strain is below 1.10 g ml
21
(Chang et al., 2007; Gastaminza et al., 2006). These
biophysical properties are similar to HCV obtained from
the blood of infected patients, where HCV has been shown
to be associated with very-low-density lipoprotein (VLDL),
a lipid particle that contains triglyceride, phospholipid,
ApoB and ApoE (Andre ´ et al., 2002; Nielsen et al., 2006;
Prince et al., 1996).
The proportion of HCV circulating in blood which has low
density and is associated with VLDL varies between
patients (Kanto et al., 1995; Zahn & Allain, 2005). This
paper aims to determine the density and size of HCV from
human liver and suggest the subcellular location in which
HCV becomes associated with VLDL, information that is
currently unknown.
We have previously demonstrated the presence of viral
structural proteins in the explant liver of a patient with
HCV infection and common variable immunodeficiency
by Western blotting and immunohistochemistry (Fenwick
et al., 2006; Nielsen et al., 2004). Our present work
characterizes the HCV RNA-containing particles in this
patient’s liver by density and size and provides new insight
into the biochemical composition and assembly of HCV in
human liver.
METHODS
HCV samples from patients. Patient S6 suffered from common
variable immunodeficiency and was infected with the 1a genotype of
HCV from contaminated intravenous immunoglobulin (Christie
et al., 1997). The viral infection progressed rapidly to cirrhosis,
requiring a liver transplant. However, the transplant liver (S6b) failed
and was removed at retransplant; it was found to contain a high titre
of HCV (5610
9 IU per gram liver) (Pumeechockchai et al., 2002).
An HCV-negative liver sample was obtained from a patient with a
Klatskin tumour in the hepatic bile ducts. Cubes of 1 g either
HCV-infected liver or control HCV-negative liver were immersed in
ice-cold homogenization buffer (Nielsen et al., 2004) and a macerate
was produced using a tight-fitting Dounce homogenizer (VWR). The
collection of human serum and tissue samples was made with
informed consent and the research project was approved by the Joint
Ethics Committee of the Newcastle and North Tyneside Health
Authority, Newcastle University and University of Northumbria.
Iodixanol density gradients. Preformed iodixanol (Optiprep; Axis-
Shield) density gradients were prepared from two buffered solutions
of iodixanol at 6% (1.7 ml 60%, w/v, iodixanol, 0.34 ml 0.5 M Tris/
HCl, pH 8.0, 0.34 ml 0.1 M EDTA, pH 8.0 and 14.6 ml 0.25 M
sucrose) and 56.4% (16.0 ml 60%, w/v, iodixanol, 0.34 ml 0.5 M
Tris/HCl, pH 8.0, 0.34 ml 0.1 M EDTA, pH 8.0 and 0.34 ml 0.25 M
sucrose). The gradient was harvested from the bottom by tube
puncture using a model 184 tube piercer (Isco) and collected in 14
fractions. The density of each fraction was determined using a digital
refractometer (Atago). Self-forming iodixanol gradients (Graham
et al., 1994) were prepared by adding 0.2 ml 0.5 M Tris/HCl
(pH 8.0), 0.34 ml 0.5 M EDTA, 4.2 ml 60% (w/v) iodixanol and
1.5 ml 0.25 M sucrose into thick-walled Ti-50 polycarbonate
centrifuge tubes (Beckman). Each centrifuge tube then received
4.2 ml liver macerate and the content was thoroughly mixed to form
a homogeneous solution. These gradients were centrifuged at
50000 r.p.m. in a Beckman L8-70M ultracentrifuge using a model
Ti-50 rotor for 24 h at 4 uC and harvested manually from the top,
collecting 18 fractions of 0.5 ml each from each sample.
For electron microscopy (EM) analysis, iodixanol fractions were
dialysed against 100 mM Tris/HCl, pH 7.4, with 2 mM EDTA at
4 uC. Samples for thin sectioning were fixed with 3% glutaraldehyde
(EM grade; VWR) and embedded in LR White (London Resin).
Samples for negative staining were applied to Formvar-coated and
glow-discharged copper grids; these were washed with Sorenson’s
buffer and stained with 1% uranyl acetate. Grids were viewed on a
Philips CM 100 transmission electron microscope equipped with an
AMT CCD camera.
Quantification of HCV RNA by real-time RT-PCR. Real-time RT-
PCR (qRT-PCR) for positive-strand HCV RNA was carried out as
described previously (Mercier et al., 1999; Nielsen et al., 2004) using
primers NCR-3 and NCR-5 (Mercier et al., 1999) plus a fluorescent
probe (59-FAM-ATTCCGGTGTACTCACCGGTTCCGCAGA-TAM-
RA-39). Primers NCR-3 and -5 anneal between nucleotides 120 and
290 in the 59 non-translated region of the HCV 1a genome. The HCV
positive-strand assay was calibrated against WHO international
standard for HCV 96/790 from the National Institute of Biological
Standards and Controls. Negative-strand HCV RNA was detected
using a qRT-PCR assay with the tagged primer, NCR-9 (Komurian-
Pradel et al., 2004; Nielsen et al., 2006). NCR-9 (59-GCGTCGGC-
AGTATCGTGAATTCGACCCCCCCTCCCGGGAGAGCCAT-39; the
tag is underlined) anneals to the 39 non-translated region of the
negative strand and was used for reverse transcription. Residual RNA
template was removed with RNase A and RNase H (GE Healthcare).
The cDNA was quantified by qRT-PCR using primer NCR-8 (59-
CGTCGGCAGTATCGTGAATTC-39), which anneals to the tag
sequence of NCR-9, in combination with NCR-3 and the fluorescent
probe. To calibrate this assay, synthetic negative-strand HCV RNA
was prepared by in vitro transcription using a T7 Megascript kit
(Ambion). A 702 bp DNA fragment between nucleotides 1 and 702 of
the HCV RNA genome was cloned by RT-PCR using a forward
(59-CGCGGATCCCCCCTGTGAGGAACTACTGTCTTCAC-39; the
BamHI restriction site is underlined) and a reverse (59-CGCAAG-
CTTGCACGTAAGGGTATCGATGACCTTAC-39; the HindIII restri-
ction site is underlined) primer. The BamHI–HindIII-restricted DNA
fragment was subcloned into pBluescript (+) (Stratagene). Negative-
strand HCV RNA was synthesized from the linerized plasmid by in
S. U. Nielsen and others
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electrophoresis. The band of negative-strand HCV RNA was eluted
with SDS and the copy number was calculated from the A260
(NanoDrop).
SDS-PAGE and matrix-assisted laser desorption/ionization–
time of flight mass spectrometry (MALDI-TOF MS) analysis.
Proteins in iodixanol fractions were analysed on SDS-polyacrylamide
gradient gels (3–18%). Proteins were stained with Coomassie brilliant
blue G-250 (Sigma) and excised from the gel for MALDI-TOF MS.
Peptides generated by trypsin digestion were analysed using a Voyager
DE-STR mass spectrometer (Applied Biosystems). Protein bands were
identified by performing searches using the peptide mass fingerprint
data and the Mascot search engine program (Matrix Science),
searched against the latest NCBI protein sequence database. Only
proteins with Mascot scores above 64, which shows that the likelihood
of a correct match is significant (P,0.05), were accepted as hits.
The monoclonal antibodies (mAbs) used in Western blotting were
human anti-HCV E1 glycoprotein (1C4; hybridoma clone IGH398
from Dr A. Union, Innogenetics, Belgium), mouse anti-HCV E2
glycoprotein (AP33; from Dr A. Patel, MRC Virology unit, Glasgow,
UK), human anti-HCV core protein (B12; from Professor M.
Mondelli, University of Pavia, Italy), mouse anti-HCV NS3 protein
(MMM33; LabVision) and human anti-HCV NS4A (D10; from M.
Mondelli). The polyclonal antibodies used in Western blotting were
rabbit anti-HCV NS5A (from Professor P. Mavromara, Hellenic
Pasteur Institute, Athens, Greece) and rabbit anti-human ApoE
(DakoCytomation). Western blots were developed using ECL Plus
(GE Healthcare) and bands were semi-quantified using a GS-800-
calibrated densitometer with Quantity One software (Bio-Rad).
Quantification of lipids. Lipids in iodixanol fractions were extracted
with chloroform/methanol (Folch et al., 1957). Each 0.5 ml fraction
was mixed with 10 ml chloroform/methanol (40:60, v/v). Extraction
of lipids was performed by rotation at 11 r.p.m. for 2 h at 37 uC
followed by centrifugation at 1000 g for 5 min. The supernatant was
harvested and mixed with 1 ml 100 mM sodium phosphate, pH 7.4.
After centrifugation at 2000 g for 10 min, the lower, organic phase
was evaporated to dryness with nitrogen. The pellet was resuspended
in 100 ml 10 mM sodium phosphate, pH 8.0, containing 4% NP-40
(Roche). Lipids were measured with a Cobas Fara auto analyser
(Roche) using phospholipid assay B and free cholesterol E kit
(Wako). Triglyceride and total cholesterol were measured using kits
from Horiba ABX.
Gel filtration of lipoproteins and HCV. Superose 6 prep grade was
packed into one XK 16/100 column and one XK 16/40 column (GE
Healthcare) and the two columns were run in series. The elution
buffer contained 20 mM Tris/HCl (pH 8.0), 0.25 M sucrose, 2 mM
EDTA, 2 mM MgSO4, 2 mM MgCl2 and 0.02% NaN3. The Superose
column was calibrated using VLDL, low-density lipoprotein (LDL),
and high-density lipoprotein (HDL) purified from normal human
plasma (Mackness & Durrington, 1992; Ma ¨rz et al., 1993). Toyopearl
HW-75S (Tosoh Corporation) was packed into one XK 26/100
column. Sample (2 ml) was applied to the column; the columns were
cooled to 4 uC and run with a flow rate of 1 ml min
21. Calibration of
the Toyopearl column was performed using purified chylomicrons,
VLDL, LDL and HDL as well as carboxylated latex bead standards
(Okazaki et al., 2005; Magsphere).
A standard curve was prepared by plotting !(2log KAV) against the
bead diameter in nm (Anonymous, 2002), calculated using the
following equation:
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
{log(KAV)
p
~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
{log(Ve{V0)=(Vt{V0)
p
Ve is the elution volume for each of the standards; Vt is the total
column volume calculated as the volume of packed beads; and V0 is
the void volume, which was calculated as 1/3 of the total column
volume (Anonymous, 2002).
For immunoprecipitation, 20 ml from each fraction was added to
140 ml 10 mM Tris/HCl (pH 7.4), containing 0.25 M sucrose and
60 mg polyclonal antibody (ApoB, ApoAI and ApoE) or 10 mg mAb
[NS3, NS4A, E1 and E2 antibody (CBH-2; from Dr S. Foung, Stanford
University, USA)]. After 4 h incubation at 4 uC, 25 ml from 50%
Protein G Sepharose (Gammabind; GE Healthcare) was added and
tubes were rotated at 11 r.p.m. for 16 h. Pellets and supernatants were
separated by centrifugation at 100 g,a t4uC for 3 min. Normal rabbit
IgG (DakoCytomation) was used as control. HCV RNA in pellet and
supernatant was quantified by qRT-PCR.
RESULTS
qRT-PCR assays for positive- and negative-strand
HCV RNA
Whilst only positive-strand HCV RNA is packaged into
virus particles, both positive- and negative-strand HCV
RNA are present in virus replication complexes and serve
as intermediates in virus replication. With the aim of
determining the specificity and sensitivity of our assays for
positive and negative strand HCV RNA, dilution series
with synthetic HCV RNA were prepared. The dilutions
were used in qRT-PCR assays and the number of PCR
cycles (CT) taken to reach the fluorescence threshold was
measured (Fig. 1). A linear correlation was observed
between CT and positive strand HCV RNA (Fig. 1a). The
sensitivity of this assay was 100 copies per tube and
linearity was observed over the entire range of dilutions. In
contrast, when the assay for negative strand was used with
positive strand HCV RNA template (Fig. 1a), CT values
were between 38 and 45, which was considered a negative
result. Thus, positive strand RNA did not give a detectable
signal in the assay for negative strand. When the assay for
negative strand HCV RNA was used with negative strand
template, a linear correlation was observed between CT
values and copy number (Fig. 1b). These results confirmed
the specificity of our negative strand assay, although the
sensitivity was lower than that of the positive strand assay,
at 1000 copies per tube.
The density distribution of positive- and negative-strand
HCV RNA from liver macerate was analysed on iodixanol
gradients. Five fractions with low density (fractions 14–18)
contained 74% of the positive-strand RNA, with a peak in
fraction 15, which had a density of 1.08 g ml
21 (Fig. 1c).
These fractions also contained 90% of the negative strand,
with the peak at 1.05 g ml
21 in fraction 17 (Fig. 1d). The
ratio of positive- to negative-strand RNA was calculated for
each fraction and found to be lowest in fraction 17 (6:1),
suggesting that this fraction contains membranes where
virus assembly takes place. In iodixanol fraction 15, the
ratio was 12:1, similar to that seen in cell culture
(Quinkert et al., 2005). The percentage of HCV associated
with ApoB in each fraction was determined by immuno-
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association with ApoB was variable across the density
gradient, with a tendency for less association to occur in
the low-density fractions, where most of the HCV RNA
was detected. In fraction 15, 12% of HCV RNA was
associated with ApoB.
Distribution of lipid subclasses and proteins
within iodixanol density gradients
The distribution of lipids from HCV-infected liver S6b
within self-forming iodixanol gradients was compared with
the lipid profile for an HCV-negative liver (Fig. 2).
Cholesterol and phospholipid levels peaked in fractions
14 and 15 (Fig. 2a, b) and the distribution of these lipids
was similar in the HCV-negative liver (data not shown).
Most cholesterol (90%) was in the form of free cholesterol.
In contrast, the largest amount of triglyceride was found in
fraction 18 (Fig. 2d). The HCV-negative liver had
significantly less triglyceride in fraction 18 (P¡0.005)
and all other iodixanol fractions contained less triglyceride
than the S6b liver (Fig. 2c). The distribution within the
gradient of proteins involved in lipid metabolism was
determined by Western blotting. Caveolin-2 (Cav-2), a
marker for lipid rafts (Shi et al., 2003), showed a peak in
fractions 14–16 (Fig. 2l). Adipocyte differentiation-related
protein (ADRP), a marker for lipid droplets (Shavinskaya
et al., 2007; Targett-Adams et al., 2003), showed a peak in
fractions 16–17 (Fig. 2f). Microsomal transfer protein
(MTP), which transfers triglyceride onto the nascent
ApoB-100 molecule in the lumen of the endoplasmic
reticulum (ER) (Rustaeus et al., 1999), was widely
distributed within the gradient, with a peak in fraction
14 (Fig. 2g).
The distribution of host and viral proteins in iodixanol
fractions was also analysed using densitometry of immu-
nostained Western blots (Table 1). Host lipoprotein ApoB
showed a peak in fraction 17 (density 1.05 g ml
21). Smaller
amounts of ApoB were detected in fractions 16 and 18
(densities 1.07 and ¡1.03 g ml
21, respectively). Similar
distribution of ApoB was observed in an HCV-negative
liver (data not shown) and the distribution overlaps with
the distribution of triglyceride (Fig. 2c, d). Host ApoE was
widely distributed within the gradient with a peak in
fraction 15 (density 1.08 g ml
21). ApoAI and ADRP, other
host proteins involved in lipid metabolism, as well as lipid
raft protein Cav-2 and HCV structural proteins core, E1
and E2 also showed peak intensity in fractions 13 to 17.
Although NS3 was widely distributed in the gradient, this
viral protein also showed a peak in fraction 15, the
same fraction that contained the peak of cholesterol.
In combination, these observations suggest that the
Fig. 1. qRT-PCR assays for positive and
negative strand HCV RNA from liver. (a, b)
CT values were measured using a dilution
series of either synthetic positive strand HCV
RNA (a) or negative strand HCV RNA (b) as a
template. One primer set and probe was
designed to detect positive strand HCV RNA
($) and another primer set was designed with
a tagged primer to detect negative strand HCV
RNA (#). Each data point represents the
mean±the range of values from two determi-
nations. (c, d) The density distribution of
positive (c) and negative (d) strand HCV
RNA within iodixanol gradients of HCV-
infected liver macerate was determined ($).
The concentration of RNA is shown by bar
graphs which represent the mean±the
range of values from two determinations.
(e) Immunoprecipitation of HCV in density
gradient fractions with antibody to ApoB. The
total HCV positive-strand RNA in the pellets
and the supernatants (shaded bars) and the
HCV RNA associated with ApoB (solid bars)
was calculated as a percentage (given above
the bars) for each fraction.
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density around 1.08 g ml
21 in iodixanol gradients. A third
group of proteins was found at a higher density, around
1.12 g ml
21, and included ER protein calreticulin and
NS4A. Albumin, an abundant cytosolic protein in hepato-
cytes, showed a peak at the bottom of the gradient, in
fractions 1 and 2.
Analysis of low-density iodixanol fractions by EM
and detergent treatment
Membranes with densities of 1.08 g ml
21 from HCV-
positive and HCV-negative livers were analysed by thin
section EM (Fig. 3a, b). Bags of particles surrounded by a
lipid bilayer, some of which contained an internal structure
in the form of pentagons or hexagons, were observed (Fig.
3a). Similar structures were rarely observed in the HCV-
negative liver and lacked the regularly shaped internal
structures that were characteristic of the structures in
infected liver (Fig. 3b). Treatment with 3% NP-40
removed lipids and generated structures resembling the
HCV nucleocapsid (Fig. 3c). The density of these particles
was 1.20 g ml
21, determined by iodixanol gradient
centrifugation, with a recovery of 70% (Fig. 3d). This
density corresponds to that of the HCV nucleocapsid
(Ishida et al., 2001).
Separation of HCV RNA-containing membranes
by gel filtration
Gel filtration on Superose6 wasused to separate HCV RNA-
containing membranes by size. The column was calibrated
with purified VLDL, LDL and HDL, which eluted in three
distinct peaks (Fig. 4a). The molecular mass of VLDL is
between 5610
6 Da for small VLDL (VLDL2) and 10
7 Da for
large VLDL(VLDL1).LDL hasa molecular mass of 2.4610
6
Da and that of HDL is between 200 and 400 kDa (Pownall et
al., 1999). The molecular mass of VLDL1 exceeds the
exclusion limit of Superose 6 (5610
6 Da) and it therefore
elutes with the void volume. Liver homogenate was first
purified on iodixanol gradients and fractions with HCV
RNA-containing membranes of less than 1.12 g ml
21 (peaks
13–18) were applied to the gel filtration column (Fig. 4b).
All HCV RNA eluted in peak I, at the same position as
VLDL. This shows that HCV in liver macerate is within
membranes or particles which are greater than or equal to
the size of VLDL. Peak II eluted at the same position as
human serum albumin and did not contain viral RNA.
Identification of host and viral proteins in gel-
filtration peaks
Proteins in peaks I and II from Superose gel filtration of
liver macerate were analysed by SDS-PAGE (Fig. 5). Both
Fig. 2. Distribution of lipids (a–d) and proteins (e–g) involved in
lipid metabolism within iodixanol density gradient fractions 1–18.
Cholesterol (a), phospholipid (b) and triglyceride (d) were measured
in each density gradient fraction from liver S6b. Triglyceride was
also measured within density gradient fractions from an HCV-
negative liver (c). The density distribution of Cav-2 (e), ADRP (f) and
MTP (g) in liver S6b was determined by Western blotting.
Characterization of HCV particles in human liver
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1 and 2). Eight of these were excised and analysed by mass
spectrometry (Table 2). This analysis identified four
proteins in peak I, all ER proteins, and four proteins in
peak II, all cytosolic proteins. Proteins from peaks I and II
were also analysed by Western blotting, using a panel of
monoclonal and polyclonal antibodies to HCV structural
and NS proteins. Antibodies to HCV structural proteins
core, E1 and E2 identified protein bands with expected
molecular masses of 20, 31 and 62 kDa, respectively (Fig. 5,
lanes 3, 5 and 7). These structural proteins were detected in
peak I but not in peak II. The mAb to NS3 recognized a
69 kDa band in peak I (Fig. 5, lane 9). The human mAb to
NS4A recognized a 7 kDa band in peak I (Fig. 5, lane 11),
which is the expected mass for NS4A (Waris et al., 2004);
this band was absent from peak II. A 56 kDa protein band
was also detected in peaks I and II. This band was present
in the absence of primary antibody and was identified as
human IgG heavy chain. The polyclonal antibody to NS5A
recognized two bands of 55 and 58 kDa in peak I but not in
peak II (Fig. 5, lanes 13 and 14). These bands were also
detected using a monoclonal NS5A antibody from Maine
Table 1. Density distribution of host and HCV proteins from liver macerate
Albumin was most abundant in fractions 1 and 2. All of the other proteins listed were most abundant between fractions 13 and 18.
Protein Subcellular location Fraction and density (g ml
”1)*
7 9 11 13 15 16 17 18
1.15 1.14 1.13 1.12 1.08 1.07 1.05 ¡1.03
ApoB Lipoprotein 0 0 0 0 1 22 52 28
ApoE Lipoprotein 13 18 25 18 34 17 11 6
Apo AI Lipoprotein 23 27 22 34 41 35 13 7
ADRP Lipid droplet 8 9 12 20 30 34 24 13
Cav-2 Lipid rafts 0 5 8 18 32 23 2 1
Calreticulin ER lumen 5 5 42 84 41 26 6 0
MTP ER lumen 25 37 54 61 47 29 13 6
Albumin Cytosol 24 21 9 1 0 0 0 0
HCV core Structural 12 1 4 19 58 15 0 0
HCV E1 Structural 1 1 5 4 10 28 11 6
HCV E2 Structural 4 5 5 67 118 36 6 0
HCV NS3 Non-structural 17 23 22 26 72 25 24 11
HCV NS4A Non-structural 0 0 8 45 8 7 0 0
*Proteins in iodixanol gradient fractions were analysed by Western blotting and semi-quantified by densitometry.
Fig. 3. Thin-section EM of fraction 15 from
iodixanol gradients of HCV-positive liver (a) or
a control HCV-negative liver (b). The fraction
from the HCV-positive liver had a density of
1.08 g ml
”1. The arrow points to an isolated
particle which shows internal structure in the
form of a pentagon; the diameter of this is
100 nm and the width of the membrane
surrounding the particle is 10 nm. (c)
Iodixanol fraction 15 was treated with 3%
NP-40 and analysed by negative-staining EM.
The density ($) and concentration (bars) of
HCV RNA following this treatment (d) indicate
that it shifted the density of HCV RNA to 1.2 g
ml
”1, corresponding to the density of the HCV
nucleocapsid (Ishida et al., 2001).
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munication). These proteins are similar in size to the 56
and 58 kDa basally phosphorylated or hyper-phosphory-
lated forms of NS5A that were previously observed using in
vitro expression systems (Neddermann et al., 1999),
suggesting that phosphorylated variants of NS5A are
present in the HCV-infected human liver. A 66 kDa
protein which co-migrated with human albumin was
detected by the NS5A antibody (Fig. 5, lane 14), possibly
as a result of cross-reactivity. The largest amount of ApoB
and ApoE was found in peak I, although a small
proportion of ApoE was observed in peak II (Fig. 5, lane
16).
Separation of HCV RNA-containing membranes
on Toyopearl
The high exclusion limit of Toyopearl S75 enabled
separation of vesicles with larger diameters, up to
40610
6 Da, compared with separation on Superose, and
allowed the resolution of purified chylomicrons, VLDL and
LDL (Fig. 6a). When serum from patient S6 was analysed
on Toyopearl, HCV RNA eluted with VLDL1 (Fig. 6a).
This showed that HCV in serum is similar in size to
VLDL1, with a diameter in the region of 60 nm, and
supports our previous determination of the HCV diameter
by sedimentation analysis (Nielsen et al., 2006). HCV RNA
from liver eluted in a broad peak from the Toyopearl
column (Fig. 6b), indicating that most HCV in liver was
within membranes with diameter ¢100 nm. However,
some HCV in the liver eluted at the same position as HCV
from serum, between fractions 20 and 24. Toyopearl
fractions 10 to 16 from liver S6b had a low positive-/
negative-strand ratio (minimum 6:1), which suggested
that these fractions contain more of the replication
complexes for HCV (Fig. 6c). Toyopearl fractions 20 to
24 had a high positive:negative strand ratio (maximum
45:1). These fractions had high relative association with
ApoB (up to 75%, Fig. 6d) and HCV RNA was associated
with ApoE, ApoAI and HCV E2 (Supplementary Table S1,
available in JGV Online). In contrast, viral RNA in
Toyopearl-separated fractions 10 to 16 was immunopreci-
pitated with the NS3 antibody but not with antibodies to
HCV E1 or E2 (Supplementary Table S1).
DISCUSSION
Blood samples and the transplant liver from patient S6
were obtained early, during the acute phase of HCV
reinfection. These circumstances provided a unique
opportunity to study HCV infection in vivo and to
characterize the native virus. These samples are also unique
as the patient’s common variable immunodeficiency
enabled us to study virus particles without the complica-
tions of host antibodies binding to the virus.
The HCV replication complex contains both positive and
negative strand HCV RNA and, in in vitro systems, the
ratio of the two falls to between 6:1 and 12:1 (Quinkert et
al., 2005). Reports of the positive- to negative-strand ratio
in unfractionated HCV-RNA-positive livers vary widely,
from 1:1 to 1100:1 (Chang et al., 2003; Komurian-Pradel
et al., 2004; Negro et al., 1998). This variability may reflect
the difficulties of precise and specific RNA quantification
that occur with low copy numbers of viral RNA in such a
complex milieu.
HCV replication complexes have been found associated
with lipid rafts and lipid droplets (Aizaki et al., 2004; El-
Hage & Luo, 2003; Quinkert et al., 2005). The membranes
in iodixanol fraction 15 (positive:negative strand ratio
12:1) peak at a density of 1.08 g ml
21 and they were
enriched in HCV structural and NS proteins, Cav-2,
ADRP, phospholipid and cholesterol . This density is
somewhat lower than the bulk of the ER proteins, e.g.
calreticulin and MTP, which are found at a density of
1.12 g ml
21. The low density of membranes containing
positive and negative strand HCV RNA suggests that virus
replication and assembly occur on structures containing
Fig. 4. Separation of HCV RNA-containing particles from liver
S6b by gel filtration on Superose 6. (a) The column was calibrated
using purified lipoproteins and albumin. Peaks corresponding to
VLDL, LDL, HDL and albumin are labelled. (b) Gel-filtration of liver
macerate first purified on iodixanol gradients, with density below
1.12 g ml
”1. Bars show the titre of positive strand HCV RNA in
fractions collected from the column. The line shows the A280 of
proteins eluting from the gel filtration column. The analysis was
repeated four times with similar results.
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Kapadia & Chisari (2005) and Miyanari et al. (2007).
The peaks of ApoB and triglyceride were found in
iodixanol fractions that had a density below 1.06 g ml
21;
this density fraction contains Golgi-derived vesicles
(Plonne et al., 1999). Phospholipid, cholesterol and ApoE
peaked at slightly higher densities, corresponding with the
peaks of positive and negative strand HCV RNA. Other
members of the family Flaviviridae, such as Dengue virus
and Kunjin virus, have been found to replicate in vesicle
packets that are virus-induced membrane structures in the
perinuclear region (Uchil & Satchidanandam, 2003;
Westaway et al., 1997). The assembly of VLDL also occurs
in the ER and Golgi, with clusters of lipoproteins
accumulating in the Golgi lumen (Tran et al., 2002). Our
results suggest that the assembly of HCV is linked to the
assembly of VLDL, as has recently been suggested by
Gastaminza et al. (2008). However, ApoB was observed in
fractions of slightly lower density than the peak of positive
and negative strand HCV RNA, suggesting that viral
replication occurs on membranes with higher density than
the Golgi clusters filled with VLDL particles.
We found that NS3, NS4A and NS5A co-fractionated with
HCV RNA and host VLDL on a Superose 6 gel-filtration
column and that those viral proteins had similar molecular
masses in human liver as they did in recombinant
Fig. 5. Identification of host and viral proteins
after separation by gel filtration. Proteins from
gel filtration peaks I and II (Fig. 4b) were
analysed by SDS-PAGE (lanes 1 and 2) and
Western blotting (lanes 3 to 16). HCV core
protein (20 kDa, lane 3) as well as HCV
glycoprotein E1 (31 kDa, lane 5) and glyco-
protein E2 (62 kDa, lane 7) were detected in
peak I but not in peak II (lanes 4, 6 and 8).
HCV proteins NS3 (62 kDa, lane 9) and NS4A
(7 kDa, lane 11) were also detected in peak I,
but not in peak II (lanes 10 and 12). The
antibody to HCV NS5A recognized two bands
of 55 and 58 kDa in peak I (lane 13). These
bands were not present in peak II (lane 14), but
cross-reactivity to albumin at 66 kDa was
observed. Host lipoprotein ApoE with molecu-
lar mass 36 kDa was recognized in peaks I and
II (lanes 15 and 16). Proteins A–H in lanes 1
and 2 were excised and identified by MALDI–
TOF (Table 2). Lane M, molecular mass
marker.
Table 2. Identification of host proteins in peaks from gel filtration of human liver macerate
The protein bands were excised from SDS-PAGE gels and the letters assigned to each protein band are shown in Fig. 5, lanes 1 and 2.
Human protein Cellular
location
Protein band Observed
mass (kDa)
Database mass
(kDa)
Probability
score*
Sequence
coverageD
Endoplasmin ER A 100 92.4 209 38
NADPH cytochromeP450 reductase ER B 75 76.5 88 27
Annexin VI ER C 68 75.8 168 40
Glutathione S transferase ER D 16 17.5 86 74
Serum albumin Cytosol E 66 65.6 276 62
Superoxide dismutase (Cu-Zn) Cytosol F 19 15.9 94 79
Haemoglobin b chain Cytosol G 15 15.7 127 65
Haemoglobin a chain Cytosol H 14 14.9 92 49
*Probability score greater than 64 indicates a significant match with a protein from the NCBI database (P,0.05).
DPercentage of protein sequence covered by peptides identified in mass spectrometry analysis.
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2006; Nomura-Takigawa et al., 2006). The detection of 55
and 58 kDa bands with anti-NS5A suggests that the
variably phosphorylated forms of this protein observed in
vitro may also exist in vivo.
Gel filtration of HCV from serum in a matrix with a large
exclusion limit, Toyopearl, led to separation of viral RNA
from the main peak of VLDL. The diameter of HCV lipo–
viro particles from plasma was determined by gel filtration
on Toyopearl and found to be similar to the 55 nm
determined previously by sedimentation analysis
(Gastaminza et al., 2006; Nielsen et al., 2006) and by
immuno-EM (Wakita et al., 2005). This diameter is similar
to VLDL1 or chylomicron remnants, but is smaller than
chylomicrons. Diaz et al. (2006) observed that up to 50%
of HCV in plasma is associated with chylomicrons or
chylomicron remnants. Toyopearl gel filtration separated
differently sized fractions containing viral RNA. Most HCV
RNA was in membranes .100 nm in diameter that were
associated with NS3, but 8% eluted with lower diameter
and high positive-/negative-strand ratio. This viral RNA
was associated with ApoB, ApoE, HCV E1 and E2, and the
diameter corresponded to HCV from serum.
In summary, the combination of iodixanol density
gradients and gel filtration has the ability to separate
HCV RNA-containing membranes by density and size.
This analysis suggests that the association of HCV with
lipoproteins occurs in the human liver. The association
between HCV and lipoprotein has been observed by others
(Gastaminza et al., 2008; Huang et al., 2007; Moradpour et
al., 2007; Thomssen et al., 1993; Yao & Ye, 2008) and our
techniques show that there is the potential to separate
hepatitis C virions from the intracellular membranes where
virus assembly occurs.
Fig. 6. Analysis of serum and liver macerate
from patient S6 by gel filtration on Toyopearl.
The gel filtration column was calibrated with
latex beads of different sizes (indicated by
arrows) as well as with purified chylomicrons,
VLDL and LDL. The elution profiles of
these proteins are shown as solid, dashed
and dotted lines, respectively, in (a).
(a) Separation of HCV RNA in serum by gel
filtration. Bars show the mean±SD HCV RNA
in each fraction. (b) Elution profile of total
protein (line). Bars show mean±SD (from three
determinations) of HCV RNA from liver macer-
ate with density below 1.12 g ml
”1. (c) The
ratio of HCV positive strand RNA and HCV
negative strand RNA for each fraction. The
proportion of HCV RNA within fractions
enclosed by brackets is shown as a percent-
age. (d) Immunoprecipitation of HCV with
antibody to ApoB. The total HCV RNA in the
pellets and the supernatants (shaded bars)
and the HCV RNA associated with ApoB
(solid bars) was calculated as a percentage
(given above the bars) for each fraction.
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